Trial Profile
mRNA Expression as a Biomarker of Xolair (Omalizumab) Response
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 30 Apr 2012 New trial record